Cooper Companies (NASDAQ:COO) Director Purchases 10,000 Shares of Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Lawrence Kurzius bought 10,000 shares of Cooper Companies stock in a transaction that occurred on Wednesday, September 16th. The shares were acquired at an average price of $54.93 per share, with a total value of $549,300.00. Following the completion of the acquisition, the director directly owned 31,099 shares of the company’s stock, valued at $1,708,268.07. This represents a 47.40% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Monday, September 14th, Lawrence Kurzius purchased 10,000 shares of Cooper Companies stock. The stock was acquired at an average price of $53.91 per share, for a total transaction of $539,100.00.

Cooper Companies Price Performance

Shares of NASDAQ COO traded down $0.83 during trading on Thursday, hitting $53.78. The company had a trading volume of 5,582,704 shares, compared to its average volume of 2,534,851. The Cooper Companies, Inc. has a 52 week low of $51.01 and a 52 week high of $89.83. The business’s 50-day moving average is $70.58 and its 200 day moving average is $68.98. The company has a market cap of $10.23 billion, a P/E ratio of 18.35, a PEG ratio of 2.17 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.03. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The company’s revenue was up .5% compared to the same quarter last year. During the same period last year, the company posted $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities research analysts predict that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies announced that its Board of Directors has approved a stock repurchase plan on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Several directors bought Cooper Companies shares after the selloff, including Paul Keel, Lawrence Kurzius, and Walter Rosebrough Jr., who collectively purchased roughly $1.33 million of stock. The insider buying may signal that management and board members view the recent decline as excessive. Insider purchase reports
• Positive Sentiment: The company’s $1.15 adjusted earnings per share exceeded the $1.12 consensus estimate, and its board authorized a $3 billion share-repurchase program. These factors could provide longer-term support if operating performance stabilizes. Cooper Companies financial information
• Neutral Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Cooper Companies investors. Similar investigations were also announced by Bragar Eagel & Squire and Levi & Korsinsky. The announcements do not establish wrongdoing, but they add legal and headline risk. Pomerantz investigation announcement
• Negative Sentiment: Investors remain concerned about U.S. channel inventory reductions, or destocking, revealed with the third-quarter results. The issue raises questions about near-term sales momentum and how quickly distributor inventories will normalize. HBSS inventory report
• Negative Sentiment: Cooper Companies lowered its fiscal 2026 revenue outlook to approximately $4.23–$4.25 billion from $4.29–$4.32 billion and reduced adjusted EPS guidance to $4.51–$4.55 from $4.58–$4.66. The cuts reflect softer contact-lens demand, particularly at CooperVision, and have prompted analysts to lower valuation targets. Levi and Korsinsky announcement

Wall Street Analyst Weigh In

Several analysts have issued reports on COO shares. Citigroup restated a “neutral” rating and set a $60.00 price objective (down from $80.00) on shares of Cooper Companies in a report on Thursday, September 10th. Piper Sandler cut shares of Cooper Companies from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $86.00 to $59.00 in a report on Thursday, September 10th. Needham & Company LLC decreased their target price on shares of Cooper Companies from $86.00 to $73.00 and set a “buy” rating for the company in a report on Thursday, September 10th. Bank of America reissued a “neutral” rating and issued a $65.00 target price (down from $80.00) on shares of Cooper Companies in a research report on Thursday, September 10th. Finally, Wall Street Zen lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Five investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Cooper Companies currently has an average rating of “Hold” and a consensus target price of $71.47.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Avalon Trust Co purchased a new stake in Cooper Companies in the 2nd quarter worth about $25,000. Root Financial Partners LLC grew its stake in Cooper Companies by 104.5% during the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 162 shares in the last quarter. SJS Investment Consulting Inc. increased its holdings in shares of Cooper Companies by 107.5% in the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 187 shares during the period. Elevation Wealth Partners LLC increased its holdings in shares of Cooper Companies by 1,136.4% in the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 375 shares during the period. Finally, Continuum Advisory LLC purchased a new stake in shares of Cooper Companies in the second quarter worth approximately $30,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.